Compare ANIX & HNNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANIX | HNNA |
|---|---|---|
| Founded | 1982 | 1989 |
| Country | United States | United States |
| Employees | N/A | 18 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.8M | 80.0M |
| IPO Year | 2013 | N/A |
| Metric | ANIX | HNNA |
|---|---|---|
| Price | $2.74 | $10.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $8.67 | N/A |
| AVG Volume (30 Days) | ★ 158.6K | 6.7K |
| Earning Date | 05-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 5.57% |
| EPS Growth | ★ 12.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $210,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.77 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.32 | $8.90 |
| 52 Week High | $5.46 | $13.19 |
| Indicator | ANIX | HNNA |
|---|---|---|
| Relative Strength Index (RSI) | 51.99 | 51.58 |
| Support Level | $2.38 | $9.71 |
| Resistance Level | $3.12 | $10.28 |
| Average True Range (ATR) | 0.19 | 0.23 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 61.54 | 59.84 |
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
Hennessy Advisors Inc is an investment management company that manages and markets open-end mutual funds branded as the Hennessy Funds. It offers domestic equity, multi-asset sectors, specialty products, and fixed income products. The company earns revenues mainly from investment advisory services and secondarily from shareholder services. Advisory services include managing each fund's portfolio in line with its investment objectives, monitoring compliance and performance, overseeing sub-advisors and other service providers, and handling marketing, distribution, and regulatory reporting. Shareholder services cover investor support and coordination with the fund service provider, with all related fees based on the funds' average daily net asset values.